0001493152-18-008888.txt : 20180619 0001493152-18-008888.hdr.sgml : 20180619 20180619085943 ACCESSION NUMBER: 0001493152-18-008888 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20180619 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180619 DATE AS OF CHANGE: 20180619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VBI Vaccines Inc/BC CENTRAL INDEX KEY: 0000764195 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37769 FILM NUMBER: 18906281 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-830-3031 MAIL ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: SciVac Therapeutics Inc. DATE OF NAME CHANGE: 20150717 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD. DATE OF NAME CHANGE: 20100910 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD DATE OF NAME CHANGE: 19850305 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 19, 2018

VBI VACCINES INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada

001-37769

N/A

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

222 Third Street, Suite 2241

Cambridge, Massachusetts

02142

(Address of principal executive offices)

(Zip Code)

(617) 830-3031

(Registrant’s telephone number, including area code)

N/A

(Former Name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

Item 8.01 Other Events.

On June 19, 2018, VBI Vaccines Inc. issued a press release announcing that Jeff Baxter, President and CEO, will present at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at 10:30 a.m. ET at the St. Regis Hotel in New York. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press Release dated June 19, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VBI Vaccines Inc.

Date: June 19, 2018	By:	/s/ Jeff Baxter
		Jeff Baxter
		President and Chief Executive Officer

EX-99.1 2 ex99-1.htm

VBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference

CAMBRIDGE, Mass. (June 19, 2018) – VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at 10:30 a.m. ET at the St. Regis Hotel in New York.

●	Event: JMP Securities Life Sciences Conference
●	Date: Thursday, June 21, 2018
●	Time: 10:30 – 10:55 AM ET
●	Event Website: http://jmpls.ljfevents-rsvp.com

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac®, a hepatitis B (HBV) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac® is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (CMV) and glioblastoma (GBM). VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

●	Website Home: http://www.vbivaccines.com/
●	News and Insights: http://www.vbivaccines.com/wire/
●	Investors: http://www.vbivaccines.com/investors/

VBI Contact

Nicole Anderson, Communications Executive

Phone: (617) 830-3031 x124

Email: info@vbivaccines.com

VBI Investor Contact

Nell Beattie

Chief Business Officer

Email: IR@vbivaccines.com

VBI Media Contact

Justin Jackson

Burns McClellan, Inc.

Phone: (212) 213-0006

Email: jjackson@burnsmc.com

Cautionary Statement on Forward-Looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The company cautions that such statements involve risks and uncertainties that may materially affect the company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the company's products. A discussion of these and other factors, including risks and uncertainties with respect to the company, is set forth in the Company's filings with the Securities and Exchange Commission and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2018, and filed with the Canadian security authorities at sedar.com on February 26, 2018, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end